featured
Residual Inflammatory Risk Associated With IL-18 and IL-6 After Successful IL-1β Inhibition With Canakinumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
European Heart Journal